308 et al. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children’s Oncology Group Report. Biol Blood Marrow Transplant 2016, 22, 782–795, doi:10.1016/j.bbmt.2016.01.023 11. Ifversen, M.; Meisel, R.; Sedlacek, P.; Kalwak, K.; Sisinni, L.; Hutt, D.; Lehrnbecher, T.; Balduzzi, A.; Diesch, T.; Jarisch, A.; et al. Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Front Pediatr 2021, 9, 705179, doi:10.3389/ fped.2021.705179 12. Patel, S.R.; Ortín, M.; Cohen, B.J.; Borrow, R.; Irving, D.; Sheldon, J.; Heath, P.T. Revaccination with Measles, Tetanus, Poliovirus, Haemophilus Influenzae Type B, Meningococcus C, and Pneumococcus Vaccines in Children after Hematopoietic Stem Cell Transplantation. Clin Infect Dis 2007, 44, 625–634, doi:10.1086/511641 13. Cordonnier, C.; Einarsdottir, S.; Cesaro, S.; Di Blasi, R.; Mikulska, M.; Rieger, C.; de Lavallade, H.; Gallo, G.; Lehrnbecher, T.; Engelhard, D.; et al. Vaccination of Haemopoietic Stem Cell Transplant Recipients: Guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019, 19, e200–e212, doi:10.1016/S1473-3099(18)30600-5 14. Bacigalupo, A.; Metafuni, E.; Amato, V.; Marquez Algaba, E.; Pagano, L. Reducing Infectious Complications after Allogeneic Stem Cell Transplant. Expert Rev Hematol 2020, 13, 1235–1251, do i:10.1080/17474086.2020.1831382 15. Girmenia, C.; Raiola, A.M.; Piciocchi, A.; Algarotti, A.; Stanzani, M.; Cudillo, L.; Pecoraro, C.; Guidi, S.; Iori, A.P.; Montante, B.; et al. Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 2014, 20, 872–880, doi:10.1016/j.bbmt.2014.03.004 16. Foord, A.M.; Cushing-Haugen, K.L.; Boeckh, M.J.; Carpenter, P.A.; Flowers, M.E.D.; Lee, S.J.; Leisenring, W.M.; Mueller, B.A.; Hill, J.A.; Chow, E.J. Late Infectious Complications in Hematopoietic Cell Transplantation Survivors: A Population-Based Study. Blood Adv 2020, 4, 1232–1241, doi:10.1182/bloodadvances.2020001470 17. Girmenia, C.; Barosi, G.; Piciocchi, A.; Arcese, W.; Aversa, F.; Bacigalupo, A.; Bandini, G.; Bosi, A.; Busca, A.; Castagnola, E.; et al. Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 2014, 20, 1080–1088, doi:10.1016/j.bbmt.2014.02.018 18. Maertens, J.; Cesaro, S.; Maschmeyer, G.; Einsele, H.; Donnelly, J.P.; Alanio, A.; Hauser, P.M.; Lagrou, K.; Melchers, W.J.G.; Helweg-Larsen, J.; et al. ECIL Guidelines for Preventing Pneumocystis Jirovecii Pneumonia in Patients with Haematological Malignancies and Stem Cell Transplant Recipients. J Antimicrob Chemother 2016, 71, 2397–2404, doi:10.1093/jac/dkw157 19. Robin, C.; Thiebaut, A.; Alain, S.; Sicre de Fontbrune, F.; Berceanu, A.; D’Aveni, M.; Ceballos, P.; Redjoul, R.; Nguyen-Quoc, S.; Bénard, N.; et al. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program. Biol Blood Marrow Transplant 2020, 26, 978–984, doi:10.1016/j.bbmt.2020.01.027 20. Styczyński, J.; Tridello, G.; Xhaard, A.; Medinger, M.; Mielke, S.; Taskinen, M.; Blijlevens, N.; Rodriguez, M.A.B.; Solano, C.; Nikolousis, E.; et al. Use of Letermovir in Off-Label Indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation Retrospective Study. Bone Marrow Transplant 2021, 56, 1171–1179, doi:10.1038/s41409-020-01166-w 21. Styczynski, J.; Reusser, P.; Einsele, H.; de la Camara, R.; Cordonnier, C.; Ward, K.N.; Ljungman, P.; Engelhard, D.; Second European Conference on Infections in Leukemia Management of HSV, VZV and EBV Infections in Patients with Hematological Malignancies and after SCT: Guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009, 43, 757–770, doi:10.1038/bmt.2008.386 22. Henze, L.; Buhl, C.; Sandherr, M.; Cornely, O.A.; Heinz, W.J.; Khodamoradi, Y.; Kiderlen, T.R.; Koehler, P.; Seidler, A.; Sprute, R.; et al. Management of Herpesvirus Reactivations in Patients with Solid Tumours and Hematologic Malignancies: Update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on Herpes Simplex Virus Type 1, Herpes Simplex Virus Type 2, and Varicella Zoster Virus. Ann Hematol 2022, 101, 491– 511, doi:10.1007/s00277-021-04746-y 23. Stadtmauer, E.A.; Sullivan, K.M.; El Idrissi, M.; Salaun, B.; Alonso Alonso, A.; Andreadis, C.; Anttila, V.-J.; Bloor, A.J.; Broady, R.; Cellini, C.; et al. Adjuvanted Recombinant Zoster Vaccine in Adult Autologous Stem Cell Transplant Recipients: Polyfunctional Immune Responses and Lessons for Clinical Practice. Hum Vaccin Immunother 2021, 17, 4144–4154, doi:10.1080/21645515.2021.1953 346 24. Baumrin, E.; Izaguirre, N.E.; Bausk, B.; Feeley, M.M.; Bay, C.P.; Yang, Q.; Ho, V.T.; Baden, L.R.; Issa, N.C. Safety and Reactogenicity of the Recombinant Zoster Vaccine after Allogeneic Hematopoietic Cell Transplantation. Blood Adv 2021, 5, 1585–1593, doi:10.1182/bloodadvances.2020003749 25. Withers, B.; Clancy, L.; Burgess, J.; Simms, R.; Brown, R.; Micklethwaite, K.; Blyth, E.; Gottlieb, D. Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program. Biol Blood Marrow Transplant 2018, 24, 2433–2442, doi:10.1016/j.bbmt.2018.08.024 26. Leen, A.M.; Bollard, C.M.; Mendizabal, A.M.; Shpall, E.J.; Szabolcs, P.; Antin, J.H.; Kapoor, N.; Pai, S.-Y.; Rowley, S.D.; Kebriaei, P.; et al. Multicenter Study of Banked Third-Party Virus-Specific T Cells to Treat Severe Viral Infections after Hematopoietic Stem Cell Transplantation. Blood 2013, 121, 5113–5123, doi:10.1182/blood-2013-02-486324 27. Hirsch, H.H.; Martino, R.; Ward, K.N.; Boeckh, M.; Einsele, H.; Ljungman, P. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus. Clin Infect Dis 2013, 56, 258–266, doi:10.1093/cid/cis844 28. Ljungman, P.; de la Camara, R.; Mikulska, M.; Tridello, G.; Aguado, B.; Zahrani, M.A.; Apperley, J.; Berceanu, A.; Bofarull, R.M.; Calbacho, M.; et al. COVID-19 and Stem Cell Transplantation; Results from an EBMT and GETH Multicenter Prospective Survey. Leukemia 2021, 35, 2885–2894, doi:10.1038/s41375-021-01302-5 29. Cesaro, S.; Ljungman, P.; Mikulska, M.; Hirsch, H.H.; von Lilienfeld-Toal, M.; Cordonnier, C.; Meylan, S.; Mehra, V.; Styczynski, J.; Marchesi, F.; et al. Recommendations for the Management of COVID-19 in Patients with Haematological Malignancies or Haematopoietic Cell Transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia 2022, doi:10.1038/s41375-022-01578-1.
RkJQdWJsaXNoZXIy ODUzNzk5